ctDNA and CTCs in Liquid Biopsy – Current Status and Where We Need to Progress

Neumann, Martin; Bender, Sebastian; Krahn, Thomas; Schlange, Thomas

doi:10.1016/j.csbj.2018.05.002

Cited by 170 publications

(149 citation statements)

References 65 publications

Supporting

Mentioning

139

Contrasting

Unclassified

Order By: Relevance

“…First, there is a dearth of consistent, reproducible and trustworthy protocols encompassing the blood sample collection, isolation and purification of ctDNA from blood and transport. Without uniform and optimized guidelines for the procedures, poor preanalytical sample handling techniques could weaken the test results, introduce additional costs, or even lead to adverse events in some patients [183]. For instance, there is great discordance between the use of ctDNA collecting tubes, which mainly include ethylenediaminetetraacetic acid (EDTA), CellSave, cell-Free DNA blood collection tubes (BCTs) and Streck.…”

Section: The Drawbacks Of Ctdna In Clinical Applicationsmentioning

confidence: 99%

The interplay of circulating tumor DNA and chromatin modification, therapeutic resistance, and metastasis

Zhang

Liang

et al. 2019

Mol Cancer

View full text Add to dashboard Cite

Peripheral circulating free DNA (cfDNA) is DNA that is detected in plasma or serum fluid with a cell-free status. For cancer patients, cfDNA not only originates from apoptotic cells but also from necrotic tumor cells and disseminated tumor cells that have escaped into the blood during epithelial-mesenchymal transition. Additionally, cfDNA derived from tumors, also known as circulating tumor DNA (ctDNA), carries tumor-associated genetic and epigenetic changes in cancer patients, which makes ctDNA a potential biomarker for the early diagnosis of tumors, monitory and therapeutic evaluations, and prognostic assessments, among others, for various kinds of cancer. Moreover, analyses of cfDNA chromatin modifications can reflect the heterogeneity of tumors and have potential for predicting tumor drug resistance.

show abstract

Section: The Drawbacks Of Ctdna In Clinical Applicationsmentioning

confidence: 99%

The interplay of circulating tumor DNA and chromatin modification, therapeutic resistance, and metastasis

Zhang

Liang

et al. 2019

Mol Cancer

View full text Add to dashboard Cite

show abstract

“…In contrast, liquid biopsy where analysis is based on fluid sample such as blood offers noninvasive continuous heterogeneous and comprehensive disease observation technique. Diversity of required information about the type, stage of the tumor, and chemotherapy progress from personalized medicine can be accessible from time to time through detection of ctDNA by this liquid biopsy [33]. The required procedures for tissue biopsy and liquid biopsy are described as a comparison in Figures 3 and 4.…”

Section: Laboratory Liquid Biopsy Techniquesmentioning

confidence: 99%

ctDNA Detection in Microfluidic Platform: A Promising Biomarker for Personalized Cancer Chemotherapy

Gauri

Ahmad

2020

Journal of Sensors

View full text Add to dashboard Cite

Early detection and characterization of circulating tumor DNA (ctDNA) can reveal mint of comprehensive biological insights from indicating the presence of tumor, identifying mutational changes of malignant cells, and allowing precision or targeted therapy together with monitoring disease progression, treatment resistance, and relapse of the disease. Apart from these, one of the greatest axiomatic implications of ctDNA detection is that it provides a new shed of light as noninvasive liquid biopsy as a replaceable procedure of surgical tumor biopsy. Despite the tremendous potential of ctDNA in cancer research, there remains a paucity of quantitative study on ctDNA detection and analysis. The majority of previously published microfluidic-based studies have focused on circulating tumor cell (CTC) detection and have failed to address the potential of ctDNA. The studies on microfluidic ctDNA detection are not consistent might be due to the complexity of ctDNA isolation as they present in low concentration in blood plasma. Researchers need to leverage the ability of microfluidic system for ctDNA analysis so that the significant enigma about cancer can be resolved effectively. This study, therefore, highlights the importance of ctDNA as cancer biomarker for liquid biopsy and provides an overview of the current laboratory as well as microfluidic techniques for ctDNA detection. This paper also attempts to show the emergence of new strands of microfluidic ctDNA detection and analysis for personalized cancer chemotherapy.

show abstract

“…CTCs and ctDNAs derived from primary or metastatic cells are abundant in blood. Both CTC and ctDNA provide prognostic information based on the number and level of events detected [70][71][72] (Table 1).…”

Section: Circulating Tumour Dna (Ctdna)mentioning

confidence: 99%

Carbonic anhydrase IX as a novel candidate in liquid biopsy

Guler

Supuran

Capasso

2019

Journal of Enzyme Inhibition and Medicinal Chemistry

View full text Add to dashboard Cite

Among the diagnostic techniques for the identification of tumour biomarkers, the liquid biopsy is considered one that offers future research on precision diagnosis and treatment of tumours in a non-invasive manner. The approach consists of isolating tumor-derived components, such as circulating tumour cells (CTC), tumour cell-free DNA (ctDNA), and extracellular vesicles (EVs), from the patient peripheral blood fluids. These elements constitute a source of genomic and proteomic information for cancer treatment. Within the tumour-derived components of the body fluids, the enzyme indicated with the acronym CA IX and belonging to the superfamily of carbonic anhydrases (CA, EC 4.2.1.1) is a promising aspirant for checking tumours. CA IX is a transmembrane-CA isoform that is strongly overexpressed in many cancers being not much diffused in healthy tissues except the gastrointestinal tract. Here, it is summarised the role of CA IX as tumour-associated protein and its putative relationship in liquid biopsyfor diagnosing and monitoring cancer progression. ARTICLE HISTORY

show abstract

ctDNA and CTCs in Liquid Biopsy – Current Status and Where We Need to Progress

Cited by 170 publications

References 65 publications

The interplay of circulating tumor DNA and chromatin modification, therapeutic resistance, and metastasis

The interplay of circulating tumor DNA and chromatin modification, therapeutic resistance, and metastasis

ctDNA Detection in Microfluidic Platform: A Promising Biomarker for Personalized Cancer Chemotherapy

Carbonic anhydrase IX as a novel candidate in liquid biopsy

Contact Info

Product

Resources

About